• Explore /
  • Poster
  • / E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).

E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).

Abstract Poster

Authors

null

Howard S. Hochster

Department of Medical Oncology, Yale University School of Medicine, New Haven, CT

Howard S. Hochster , Paul J. Catalano , Edith P. Mitchell , Deirdre Jill Cohen , Peter J. O'Dwyer , Al Bowen Benson III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01079780

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr TPS793)

DOI

10.1200/jco.2015.33.3_suppl.tps793

Abstract #

TPS793

Poster Bd #

F31

Abstract Disclosures

Similar Posters

First Author: Howard S. Hochster

First Author: Ying Liu

First Author: Dominik Paul Modest

First Author: Kanwal Pratap Singh Raghav